Platelets undergo apoptosis in response to a variety of stimuli in the circulation. Mitochondria in platelets are essential for their apoptosis. Specifically, pro-survival protein BCL-x L on mitochondria is the key regulator of platelet lifespan. Here we identify an outer mitochondrial membrane protein FUNDC2 for platelet survival. FUNDC2 knockout mice carrying excessively apoptotic platelets exhibit thrombocytopenia in response to hypoxia. Mechanistically, FUNDC2 binds the lipid PIP3 via its unique, highly conserved N-terminal motif. FUNDC2 deficiency abrogates the phosphorylation of AKT and its substrate BAD in a PIP3/PI3K-dependent manner, which suppresses BCL-x L . Indeed, FUNDC2 deficiency shortens the platelet lifespan under stress. Thus, this FUNDC2/AKT/BCL-x L axis signifies a balance between platelet survival and apoptosis at the single organelle level and provides new insight for platelet-related diseases as well.
Introduction
Platelets are small cytoplasmic fragments that contain mitochondria but no nucleus [1] . They are exposed to a diversity of stresses, such as shear force, high-oxygen, oxidative damage, and hypoxia, during their circulation in peripheral blood [2] [3] [4] [5] [6] . A number of studies have suggested that platelets can undergo apoptosis in response to various stimuli [7] [8] [9] [10] [11] . The high turnover rate of platelets, with a lifespan around 5 days in mouse or 10 days in humans [12] , also requires accurate modulation of intrinsic programmed cell death [13] . Mitochondria are essential for platelet apoptosis. They are not only the powerhouse in cells to provide energy but also contain key regulators of cell death. It has been shown that the pro-survival protein BCL-x L , which is a member of the extended B-cell lymphoma-2 (BCL-2) protein family on mitochondria [14] , is the key mediator of platelet lifespan [15, 16] . Genetic ablation of BCL-x L results in reduced platelet half-life and marked thrombocytopenia in mice. Pharmacologic inhibition of BCL-x L by ABT737, the pro-apoptotic BCL-2 homology 3 (BH3) mimetic [17] , also leads to dose-dependent thrombocytopenia [15, 18] .
The serine/threonine protein kinase AKT (also known as protein kinase B, PKB) is a central node in the regulation of cell fate [19, 20] . AKT is evoked at the cell membrane by binding to the lipid phosphatidylinositol-3,4,5-trisphosphate (PIP3) which is an important second messenger in mammalian cells [21] . Upon stimulation, AKT can translocate into the cytosol and the nucleus, as well as the mitochondria [22] , and phosphorylate a variety of substrates to promote Edited by L Scorrano * Qi Ma maq@pku.edu.cn 1 cell survival. However, whether and how AKT regulates platelet survival are still largely unknown. In this study, we identified a novel mitochondrial outer membrane protein FUNDC2 that binds PIP3 directly. FUNDC2 deficiency decreased PIP3 level and abrogated the phosphorylation of AKT and BAD. Eventually, BCLx L was inhibited by unphosphorylated BAD. Thus, FUNDC2-deficient mice displayed thrombocytopenia in response to hypoxia. The newly characterized FUNDC2/ AKT/BCL-x L signaling pathway protects platelets against apoptotic stress.
Methods

Mice
All protocols were approved by the Institutional Animal Care and Use Committee of the Institute of Zoology accredited by AAALAC International. Adult (3-5-monthaged) male animals were used in this study. For the generation of FUNDC2-null mice, the FUNDC2-targeting vector consisted of 2 genomic fragments and the neomycin resistance gene (Neo), which replaced the second coding exon of the FUNDC2 gene following homologous recombination. Embryonic stem cell clones (C57BL/ 6 strain) were used to generate chimeric mice and eventually FUNDC2-null mice. For hypoxia treatment, mice were maintained in O 2 -controlled chambers (~8% O 2 ) with a 12-h light/dark cycle and were given free access to food and water. For bone marrow transplantation, recipient mice were X-ray-irradiated at a single dose of 8.5 Gy.
Antibodies, reagents, and plasmids FUNDC2 antibody (Ab) was generated by immunizing rabbits with recombinant FUNDC2 protein and affinity purified by our laboratory. Phospho-Akt (Ser473) mouse mAb (#4051) and phospho-Bad (Ser136) rabbit mAb (#4366) were purchased from Cell Signaling. In total, 1 μg/ ml (final concentration) Abs were used for immunoblotting and 10 μg/ml for immunoprecipitation or immunostaining. Unless otherwise noted, all Abs were purchased from Cell Signaling and all chemicals were from Sigma Aldrich. Fulllength FUNDC2 was amplified from a human or mouse cDNA library by PCR. DNA fragments corresponding to full-length FUNDC2 or the indicated mutants were inserted into pCMV-N-HA vector between the EcoR I and Xho I restriction sites or pcDNA4/TO/myc-His B vector between Kpn I and Xho I. For protein expression and purification, indicated sequences were inserted into pGEX-4T-1 vector between BamH I and EcoR.
Cell culture and plasmid transfection
Primary MEFs were obtained from day E13.5 embryos of mice. MEF and HeLa cells were grown in DMEM highglucose medium (Invitrogen) with 10% FBS at 37°C and 5% CO 2 . When cells reached~60% confluence, gene transfer was performed by plasmid transfection using Lipofectamine-2000 kits (Invitrogen).
Mitochondrial fractionation
HeLa cells were collected and resuspended in hypotonic buffer (10 mM Tris, 150 mM EGTA, 200 mM sucrose, pH 7.4). After gentle homogenization with a Dounce homogenizer, cells were centrifuged at 1000×g for 10 min to remove nuclei and intact cells. Mitochondria were pelleted by centrifugation at 10,000×g for 10 min.
Protease K digestion assay
Isolated mitochondria were suspended in hypotonic buffer and incubated on ice with 100 μg/ml proteinase K containing 1% TritonX-100 or not for 30 min. Digestion was terminated by adding PMSF with a final concentration of 7 mM on ice for 5 min. Mitochondrial proteins were immunoblotted.
Immunogold electron microscopy
Platelets were fixed with 2% paraformaldehyde at 4°C overnight and dehydrated in a graded ethanol series and embedded in acrylic resin (LR White). Ultrathin sections of 70 nm were mounted on nickel grids. After blocking in PBS containing 1% BSA, samples were first incubated with primary antibody in 1% BSA at 4°C overnight, washed 5 times for 5 min in 0.5% BSA, and labeled with 20 nm or 10 nm gold-conjugated particles in 1% BSA. Later, grids were washed 5 times for 5 min in 0.5% BSA. Finally, grids were incubated for 15 min in 1% glutaraldehyde, washed twice for 5 min in PBS then 3 times in distilled water, stained, and dried at room temperature. The samples were visualized using a 120 kV Jeol electron microscope at 80 kV and images were captured using an AMT digital camera.
Immunoblotting, co-immunoprecipitation, and immunostaining
Tissues or cells were lysed in lysis buffer (30 mM HEPES, 100 mM NaCl, 0.5% Nonidet P (NP)-40, protease inhibitors mixture, pH7.6) on ice for 10 min and the lysates were centrifuged at 13,000 rpm for 10 min. For immunoblotting, proteins were resolved by SDS-PAGE transferred onto nitrocellulose membranes and detected with the indicated antibodies. For co-immunoprecipitation, immunoprecipitation was performed using the indicated antibodies, followed by immunoblotting analysis. For immunostaining, cells were transfected with the indicated plasmids and treated with the corresponding antibodies before incubation with fluorescein isothiocyanate (FITC)-, CY3-or CY5-conjugated second antibodies (DAKO). Images were collected with a laser scanning confocal microscope (LSM-700, Zeiss).
Protein purification
The vector pGEX-4T-1 containing the indicated DNA sequence was transfected into E. coli strain BL-21(DE3). Cells were grown in Luria-Bertani medium to OD600~0.6 then IPTG (0.1 mM final concentration) was added to induce the protein expression at 16°C overnight. Cells were lysed by sonication and the inclusion bodies were discarded by centrifuging at 12,000×g for 1 h. GST-fused proteins were purified using glutathione (GSH)-Sepharose 4 Fast Flow beads (Amersham Biosciences).
Protein-lipid overlay assay
Hydrophobic membranes spotted with 100 pM of indicated lipids (Echelon Biosciences) were purchased and binding assays were performed as recommended by the manufacturer. Briefly, the membranes were blocked with PBST containing 3% BSA and incubated with recombinant GST-FUNDC2 protein for 1 h at room temperature. Membranes were then analyzed by SDS-PAGE and immunoblotted with GST antibody.
Pulldown assay
For protein-lipid pulldown, 1 μg GST-fused proteins and 20 μL PIP3-coated beads (Echelon Biosciences) were mixed in 1 ml binding buffer (50 mM Tris, 150 mM NaCl, 0.05% NP-40, pH 7.5) and rotated for 15 min at room temperature. After centrifugation at 13,000 rpm for 10 min, pellets were resuspended in 1 ml binding buffer and washed 3 times. Pellets and flowthrough were analyzed by SDS-PAGE and immunoblotted with GST antibody.
Hematological analysis
Complete and differential blood cell counts were determined using automated counting techniques (Beckman Coulter).
Thrombopoietin analysis
Blood was collected from the retroorbital sinus and incubated at room temperature for 2 h. After centrifugation at 5500 rpm for 20 min, the supernatant was centrifuged again under the same conditions and serum collected. Thrombopoietin levels were measured by enzyme-linked immunosorbent assay (ELISA) using the Quantikine Mouse TPO Immunoassay kit (R&D Systems) according to the manufacturer's instructions.
Platelet preparation
Whole blood from mice was mixed with 1/10 volume of White's anticoagulant (2.94% sodium citrate, 136 mM glucose, pH 6.4). Platelet-rich plasma was obtained by centrifugation at 150×g for 10 min. Washed platelets were obtained by centrifugation at 800×g for 10 min and resuspended in modified Tyrode's buffer (12 mM NaHCO 3 , 138 mM NaCl, 5.5 mM glucose, 2.9 mM KCl, 2 mM MgCl 2 , 0.42 mM NaH 2 PO 4 , 10 mM HEPES, pH 7.4). Washed platelets were left to rest for 30 min before use.
Ex vivo assay
Rest platelets were resuspended in modified Tyrode's buffer (12 mM NaHCO 3 , 138 mM NaCl, 5.5 mM glucose, 2.9 mM KCl, 2 mM MgCl 2 , 0.42 mM NaH 2 PO 4 , 10 mM HEPES, pH 7.4) and were treated in 22°C by 8% O 2 for 2-4 h with 5 μM Z-VAD-FMK, or 5 μM LY294002, or not.
Flow cytometry analysis
For PIP3 study, platelets derived from mice were digitoninpermeabilized for 5 min on ice and labeled with PIP3 antibody/FITC-conjugated second antibody. For apoptosis analysis, platelets were stained with FITC-conjugated annexin V for quantitative apoptosis assay or tetramethylrhodamine ethyl ester (TMRE, Invitrogen) for mitochondrial membrane potential measurement. For megakaryocytes analysis, bone marrow from femurs was flushed with PBS and dispersed with a transfer pipette. After filtration through a 100 μm cell strainer, the cell suspension was centrifuged at 1000×g for 5 min. Cells were then resuspended in 1 ml PBS containing 5% FBS. Cells were labeled with phycoerythrin (PE)-conjugated anti-GPIb antibody (Emfret) and FITC-conjugated anti-CD41 antibody on ice for 30 min before flow cytometry analysis of megakaryocytes.
Platelet clearance assay
Mice were injected intravenously with 300 μg Nhydroxysuccinimido (NHS)-biotin (Sigma) in normal saline containing 10% DMSO. At various time points whole tail blood was isolated and mixed with BSGC buffer (13.6 mM tri-sodium citrate, 116 mM NaCl, 8.6 mM Na 2 HPO 4 , 0.9 mM EDTA, 1.6 mM KH 2 PO4, 11.1 mM glucose). After two centrifugation steps, the platelet pellet was resuspended in BSS buffer (149 mM NaCl, 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , 3.7 mM KCl, 1.2 mM KH 2 PO 4 , 0.8 mM K 2 HPO 4 , 7.4 mM HEPES, 3% FBS) and stained with FITCconjugated anti-CD41 antibody (BD) and PE-conjugated streptavidin (BD) for 1 h on ice. Flow cytometry analysis was performed using FACScan (BD) and all data were analyzed with Cell Quest software (BD).
Adoptive platelet transfer assay
Mice were injected intravenously with 300 μg NHS-biotin. 30 min later, platelets were isolated and resuspended in normal saline before intravenous injection into recipient mice.
Statistical analysis of data
Statistical data are presented as mean ± SEM. Significance was calculated by Student's t-test, or Mann-Whitney U test. Differences between groups were examined using one-way analysis of variance (ANOVA) or repeated-measures ANOVA. NS no statistical significance; *p < 0.05; **p < 0.01; ***p < 0.001. The number of independent experiments or mice was clarified in figure legends or in column of each figure.
Results
Identification of FUNDC2 as a mitochondrial protein
In our previous study, we found that mitochondrial protein FUNDC1 mediates mitophagy and regulates platelet functions [23, 24] . FUNDC2 (FUN14 domain-containing 2, also known as HCBP6) [25, 26] is a homolog of FUNDC1. FUNDC2 is highly conserved in vertebrates (Fig. 1a) . However, its domain structure or biological function was previously uncharacterized. First, we validated its mitochondrial localization. Confocal imaging analysis showed that HA-tagged FUNDC2 (FUNDC2-HA) localized exclusively to mitochondria in mouse fibroblasts (Fig. 1b) . Fractionation assays with HeLa cell lysates also biochemically confirmed the localization of endogenous FUNDC2 to mitochondria (Fig. 1c) . Three hydrophobic transmembrane (TM) regions in FUNDC2 (supplemental Figure S1a) were predicted using TMpred software. Our topology study demonstrated that both TM1 and TM2 are required for its mitochondrial localization (supplemental Figure S1 , b and c). Furthermore, proteinase K digestion assays revealed that FUNDC2 is localized in the outer mitochondrial membrane (OMM) with both its N-and C-termini facing the cytosol (Fig. 1d ,e).
FUNDC2 knockout mice display hypoxia-induced thrombocytopenia
FUNDC2 mRNA is ubiquitous in a variety of tissues of mice (Fig. 2a) . However, expression profiling showed an unexpected high protein level of FUNDC2 in platelets (Fig. 2b) . Immunogold electron micrographs also confirmed the enrichment of FUNDC2 on mitochondrial surface in platelets (Fig. 2c) . Moreover, its homolog FUNDC1 regulates platelet functions [24] . Thus, we focused on studying the role of FUNDC2 in platelets. To further explore the physiological relevance of FUNDC2, we established FUNDC2 knockout (KO) mice (supplemental FigureS2, a and b). Mice lacking FUNDC2 display gross normality ( Fig. 2d and supplemental FigureS3, c-e) . Specifically, FUNDC2-deficient mice displayed thrombocytopenia (platelet counts~700 × 10 3 /μl) compared to the wild-type (WT) littermates (platelet counts~1100 × 10 3 /μl) in response to chronic hypoxia, a mild stress, for 5 days (Fig. 2e) . Moreover, the thrombopoietin (TPO) levels in FUNDC2-KO or WT mice were little changed during hypoxia treatment (supplemental Figure S3a) . In contrast, other peripheral blood cells were unaffected in the loss of FUNDC2 ( Table 1 ), indicating that FUNDC2 deficiency have no effects on hematopoietic stem cells and other lineages of blood cells. Notably, hypoxia even triggered thrombocytopenia in FUNDC2-null mice after the treatment for only 1 day. However, no further decrease of platelet count was observed at the duration (14 days) of the treatment. Moreover, the thrombocytopenia could reverse in 7 days after the animals were brought back to normoxic conditions (Fig. 2f) . Platelets circulate for about 5 days in mice, thus this result implied that the platelet generation of FUNDC2 knockout mice remains unimpaired. Additionally, transplantation of bone marrow derived from WT animals rescued hypoxiainduced thrombocytopenia in FUNDC2-deficient mice. In contrast, WT mice transplanted with FUNDC2-KO bone marrow displayed decreased platelet count (Fig. 2g) . Collectively, these data suggest that the genetic ablation of FUNDC2 attenuates platelet survival. Platelets are produced from megakaryocytes in the bone marrow and spleen and eventually destroyed by the reticuloendothelial system, primarily in the liver and spleen. Spleens in FUNDC2 mutant mice were morphologically similar to those of WT counterparts (supplemental Figure S3b ) and the numbers of mature megakaryocytes with or without FUNDC2 were comparable (supplemental Figure S3, c and d ).
FUNDC2 deficiency shortens platelet lifespan in response to hypoxia stress
To monitor thrombocyte survival in the circulation, platelets were biotin-labeled and tracked in vivo. Loss of FUNDC2 reduced the platelet half-life (from~61 to~42 h) in response to hypoxia (Fig. 3a) . To further confirm that changes in circulating t 1/2 reflected properties intrinsic to platelets, we performed reciprocal adoptive transfers. Upon transfer into WT recipients, platelets in FUNDC2-null mice were cleared more quickly than those in WT animals under hypoxia stress, with half-lives comparable to those seen in WT mice. Conversely, the clearance of WT platelets transferred into FUNDC2-null mice was identical regardless of the recipient's genotype (Fig. 3b, c) . Furthermore, apoptosis markers including a decrease in mitochondrial membrane potential and phosphatidylserine exposure in FUNDC2-deficient platelets were also observed by Annexin V and TMRE staining (Fig. 3d, e) . The ex vivo assays also showed that platelets from FUNDC2-null mice were much more sensitive to apoptotic stimulation than WT ones. In addition, this hypoxia-induced apoptosis was remarkably blocked by apoptosis/caspase inhibitor Z-VAD-FMK (Fig. 3f ). All these findings reflect the protective role of FUNDC2 in platelet maintenance.
FUNDC2 selectively binds PIP3 via its PIP3-binding motif
In the study of FUNDC2 biological function, bioinformatics analysis predicted the lipid-binding potential of this protein. To verify the physical interaction between FUNDC2 and lipids, membranes spotted with a number of biologically active phospholipids and phosphoinositides were incubated with purified recombinant FUNDC2 protein. The lipid-protein overlay assay showed that FUNDC2 interacted predominantly with PIP3 (Fig. 4a) . FUNDC2 was also detected by immunoblotting after immunoprecipitation of endogenous PIP3 from HeLa cells expressing FUNDC2-HA (Fig. 4b) . Moreover, affinity pulldown assays using PIP3-coated beads and recombinant FUNDC2 (Fig. 4c) . Next, we found that deletion of a unique motif which consists of 11 amino acids abolished the PIP3-binding ability of FUNDC2. In contrast, other mutants of FUNDC2 carrying a variety of truncations had similar activities to that of the full-length protein (Fig. 4d) . Additionally, overexpression of FUNDC2 in HeLa cells recruited PIP3 to mitochondria. By contrast, the loss-offunction FUNDC2ΔPB can not recruit PIP3 to mitochondria (supplemental Figure S4a , b, and c). Consistent with the role of PIP3 in activating AKT, overexpression of FUNDC2 constitutively elevated the phosphorylation of AKT in mitochondria, but overexpression of the mutant lacking PB motif (FUNDC2ΔPB) failed to activate phospho-AKT (supplemental Figure S4d) . This PIP3-binding (PB) motif at the N terminus of FUNDC2 is highly conserved from mouse to human (Fig. 4e) , and is distinct from pleckstrin-homology (PH) domain [27] , which is well-known to bind PIP3. To further define PB motif, a polypeptide encompassing its amino acid residues (KFEALDLAEL) was synthesized. Remarkably, this polypeptide severely impaired the binding of FUNDC2 to PIP3 (Fig. 4f) , probably because it competitively interacted with PIP3. In brief, our data indicate that FUNDC2 directly and selectively binds to PIP3 via its PB motif.
FUNDC2 is essential for AKT signaling in a PIP3/ PI3K-dependent manner
Next, we performed co-immunoprecipitation assays to validate the interaction between endogenous PIP3 and FUNDC2 in resting platelets (Fig. 5a) . Moreover, immunostaining assay and ELISA both revealed that PIP3 level of FUNDC2-KO platelets was markedly reduced compared to WT mice ( Fig. 5b and supplemental Figure S5 ). PIP3 is essential for the activation of AKT kinase which regulates cell fate in mammals. Therefore, we hypothesized that FUNDC2 maintains platelet survival via the PIP3/AKT signaling pathway. Then we tested AKT phosphorylation in FUNDC2-null platelets. Markedly, FUNDC2 deficiency severely attenuated AKT phosphorylation. Furthermore, AKT phosphorylation was totally inhibited by hypoxia e Platelet counts were determined from mice treated with hypoxia for 5 days. f Mice were exposed to hypoxia and then put back in normoxia for indicated days and platelet counts were determined (n = 5-10 mice). g Transplantation (trans) of bone marrow. Mice were treated with hypoxia for 5 days (n = 6 mice) (Fig. 5c , also see Fig. 5e ). Consistently, the PIP3-independent activation of Src, ERK, or AMPK kinases remained intact in FUNDC2-deficient platelets (supplemental Figure S6 ), indicating that FUNDC2 mediates AKT activation in a PIP3-dependent manner. PI3K is essential for PIP3/AKT stimulation [20] . Thus, we tested the role of PI3K in the FUNDC2/PIP3/AKT pathway. PI3K inhibitor (LY294002) totally blocked AKT phosphorylation in WT or KO platelets (Fig. 5c) . Furthermore, LY294002 induced platelet apoptosis in WT mice in response to hypoxia, similar to KO ones (Fig. 5d ). The differences of AKT phosphorylation and platelet phenotype between WT and KO mice can be abrogated by LY294002, which suggests that FUNDC2 regulates AKT signaling pathway in a PI3K-and PIP3-dependent manner.
The FUNDC2/AKT/BCL-xL axis protects platelets from apoptosis
Next, we investigated the regulatory mechanism whereby FUNDC2/AKT maintains platelet survival. In FUNDC2-deficient platelets, AKT phosphorylation was suppressed. Consistently, the phosphorylation of BAD, which is a substrate of AKT in mitochondria [27, 28] , was also attenuated in the absence of FUNDC2. Furthermore, BAD phosphorylation was completely abrogated by hypoxia stress in KO platelets (Fig. 5e ). The dephosphorylation of BAD enhanced its inhibitory interaction with BCL-x L , a pro-survival protein on mitochondrial surface, which protects platelets from apoptosis [14] . Markedly, the amount of Bcl-x L that was coimmunoprecipitated by BAD was increased in FUNDC2- KO mice than the WT control both in hypoxia and normal conditions (Fig. 5f , and supplemental Figure S7 and S8). Thus, FUNDC2 deficiency caused defects of AKT and BAD phosphorylation, and enhanced BAD-BCL-x L interaction, which led to BCL-x L inhibition. Accordingly, FUNDC2-KO platelets are sensitive to hypoxic stress. Upon the apoptotic stimulation, the inactive BCL-x L failed to prevent downstream apoptotic cascade markers, including a decrease in mitochondrial membrane potential (Fig. 3d) , phosphatidylserine exposure (Fig. 3e) , and caspase activation (Fig. 5e) . Moreover, similar to KO mice, LY294002 also enhanced BAD-BCL-x L interaction in WT platelets (supplemental Figure S9) , which is consistent that LY294002 inhibited AKT phosphorylation (Fig. 5c ) and induced platelet apoptosis (Fig. 5d ) of WT mice. It further confirmed that FUNDC2 regulates platelets lifespan in AKT-BAD-BCL-x L signaling pathway.
Discussion
Conclusively, our overall data discovered a novel FUNDC2/ AKT/BCL-x L axis at mitochondrial surface which protects platelets from apoptosis under stress. FUNDC2 mediates AKT activation in a PIP3-and PI3K-specific manner, which suppresses the co-localized apoptosis machinery of BAD/ BCL-x L in mitochondria and provides survival advantage for platelets. FUNDC2 deficiency severely abrogates AKT phosphorylation and shortens the lifespan of circulating platelets, resulting in thrombocytopenia in response to apoptotic stress such as hypoxia. This newly characterized FUNDC2/AKT/BCL-x L axis in this report signifies a Yin and Yang balance (Fig. 5g ) in controlling platelet lifespan at the single organelle level, as well as represents an important paradigm for fate of cells with a high turnover rate. Mitochondria function as signaling hub in mammalian cells since multiple OMM proteins play as mediators in apoptosis, mitophagy, and innate immunity. Numerous mitochondrial proteins were found to be phosphorylated and much of the work was centered on translocation of kinases onto mitochondria for such effect [23, 29, 30] . Importantly, our data implicate a novel OMM protein in the regulation of mitochondrion-centered AKT signaling, which is dependent of PIP3 and PI3K. Moreover, the FUNDC2's effects on mitochondrial apoptosis and platelet counts under hypoxic stress is specific. Our previous data showed that FUNDC1 contains the LC3-interacting region (LIR) motif, which is essential for FUNDC1-mediated mitophagy in platelets [23, 24] . However, FUNDC2 does not contain the LIR motif and no mitophagy can be detected in FUNDC2-KO platelets or in cultured HeLa cells. We also found that FUNDC1 deficiency only affects mitochondrial quality and platelet activity without reducing platelet number under the identical conditions (data not shown).
Whether does FUNDC2 affect AKT signaling by interfering with mitochondrial activities? We tested the mitochondrial activities by measuring the respiratory functions in WT and FUNDC2-KO platelets, with the treatment of hypoxia or not. Despite the decrease of the oxygen consumption rate after the treatment of hypoxia, there was no difference in the KO platelets and the WT ones (supplemental Figure S10) . It suggests that the deficiency of FUNDC2 has no effects on mitochondrial metabolic functions. Moreover, pull-down assays showed that FUNDC2 have no direct interaction with AKT or PDK1, which is required for AKT phosphorylation (supplemental Figure S11) . However, whether AKT can regulate FUNDC2 in a feedback mechanism needs more research. FUNDC2 can recruit PIP3 to mitochondria using the PIP3-binding motif (supplemental Figure  S4) . In spite of the mechanism, FUNDC2 possibly plays as an anchor and mediates the transfer of PIP3 to mitochondria, and the binding of FUNDC2-PIP3 stabilize PIP3 levels, which is required for AKT phosphorylation and BAD-BCL-x L signaling. Platelets in peripheral blood are exposed to a diversity of stresses (e.g., shear force, high-oxygen, oxidative damage, and hypoxia) and undergo apoptosis in response to these stimuli [4, 15, 18, [31] [32] [33] [34] [35] [36] . Hypoxia is a major pathological mechanism that underlies atherosclerosis, myocardial infarction, acute coronary syndromes, and ischemia/reperfusion (I/R) injury. Platelets also play essential role in these cardiovascular diseases [37] [38] [39] . Thus, we used chronic and mild hypoxia as a pathological condition to treat mice. Some reports showed that early-onset thrombocytopenia was associated with placental insufficiency and hypoxia in preterm neonates, which was suggested to be the result of decreased platelet production [36] . Long-term hypoxia (~6% O 2 for 10 days) was thought to decrease platelet counts in mice, which was linked to the inhibition of production of thrombopoietin (TPO) [31, 32, 34, 35] . However, previous studies of different groups have demonstrated that hypoxia of short duration (~8% O 2 for 1-3 days) increased platelet counts [4, 33, 35] , which is consistent with our data that hypoxia (~8% O 2 for 1-4 days) increased platelets in WT mice. And we also showed that TPO is little changed during hypoxia. The mechanism by which short-term hypoxia increased platelets is still unknown. It was suggested that megakaryocytes possibly over-compensatively shed platelets into the circulation in response to hypoxia stress [4] . FUNDC2 mRNA is ubiquitous in a diversity of tissues of mice but the protein level is specifically high in platelets. The possible reason is that FUNDC2 might be highly expressed for platelet maintenance under these apoptotic stimulations. Also, platelets are anuclear and have a high turnover rate. All these may requires accurate modulation of intrinsic apoptosis specifically in a FUNDC2-dependent manner.
BCL-2 family proteins have been established for their critical role in regulating platelet lifespan. The pro-apoptotic protein BAK and anti-apoptotic BCL-x L perform antagonistic effects on intrinsic apoptosis of platelets [15] . BID and BIM, two of the pro-apoptotic BH3-only proteins, are dispensable for platelet apoptosis [40] . However, our present work showed that another BH3-only protein BAD regulates platelet survival by binding to BCL-x L , which is consistent with the phenotype that bad -/-mice exhibit thrombocytosis due to prolonged platelet life-span [41] . Thus, our findings extend the role of BCL-2 family proteins in platelet survival. FUNDC2 regulates platelet number in response to hypoxia via BCL-x L -dependent apoptosis. Our data is consistent with the findings that pharmacologic inhibition of BCL-x L by ABT737 or ABT263, both the pro-apoptotic BCL-2 homology 3 (BH3) mimetic [17] , also leads to dose-dependent thrombocytopenia [15, 18, 42] . Notably, BCL-x L inhibition not only reduced platelet count but also largely impaired platelet functions and activation [18, 42] . In our study, FUNDC2 regulates platelet apoptosis via the modulation of BCL-x L activity. Thus, it is interesting to evaluate whether FUNDC2 regulates hemostatic function of platelets in bleeding as well as in cardiovascular diseases in further studies. As platelets play essential role for blood hemostasis, wound healing, cardiovascular disease, and immunity, our study paves the new avenue for the regulation of platelet survival at the level of mitochondria and hold promises for fighting these diseases.
